投资
11投资退出
2想告知投资者类似费森尤斯医疗企业账本关于你的公司吗?
提交你的分析师简报在投资者面前,CB Insights的平台上的客户和合作伙伴。德赢体育vwin官方网站
最新的费森尤斯医疗企业账本新闻
2022年7月18日
分享这篇文章提供的新闻分享本文瓦尔哈拉殿堂,纽约,July 18, 2022 /PRNewswire/ -- Retia Medical, an innovator in advanced hemodynamic monitoring, today announced that it has secured $15 million in Series B funding. The financing round was led by Fresenius Medical Care Ventures with participation from a second strategic investor, Red Cedar Ventures, and existing investor, the Pritzker-Vlock Family Office. Retia Medical will use the funding to expand its commercial team and accelerate the development of its next-generation algorithms for guiding care for high-risk patients. "We are delighted to work with our new partners from Fresenius Medical Care, the second strategic investor, and Red Cedar Ventures to make advanced hemodynamic data accessible to as many clinicians as possible in order to help improve outcomes for high-risk surgical and critically ill patients," said Marc Zemel, S.M., M.B.A., Co-Founder and Chief Executive Officer of Retia Medical. Commenting on the investment, Al Wiegman, Head of Fresenius Medical Care Ventures, said, "This financing is an important step forward in advancing the commercialization of Retia's Argos Cardiac Output Monitor, which provides consistently accurate data to help ensure patient safety and avoid serious complications from high-risk surgeries and ICU stays. We are impressed with the strength of the Retia team, their technology, and their commitment to innovation. We are proud to lead this financing and look forward to supporting Retia through its next phase of growth." About the Argos Cardiac Output Monitor Retia Medical's Argos Cardiac Output Monitor enables individualized, data-driven care to improve outcomes and lower costs for high-risk surgical and critically ill patients. This hemodynamic monitor features the powerful Multi-Beat Analysis (MBATM) algorithm for consistently accurate cardiac output measurements. Unlike other monitors that only analyze a single beat at a time, Argos' proprietary MBA algorithm analyzes multiple heartbeats to model the patient's physiology and therefore provide high-quality hemodynamic data in real-time. The system detects important changes in a patient's status and enables immediate clinical intervention, when required. Designed to streamline care, the next-generation Argos Monitor can be set up in less than one minute and leverages a patient's existing arterial line for immediate use without requiring costly additional disposables or connections. About Retia Medical Retia Medical aims to provide accurate cardiovascular information and insights to help clinicians improve outcomes for high-risk patients. Retia brings together industry-leading expertise in physiology, signal processing, data science, and computational algorithms to engineer innovative hemodynamic monitoring solutions that give clinicians accurate, real-time data that they can rely on to make patient care decisions. Retia is committed to giving clinicians greater access to hemodynamic monitoring by providing a more cost-effective solution by eliminating unnecessary proprietary disposables. Retia Medical is proud to positively impact patient care in the U.S. and internationally as more hospitals continue to incorporate the Argos Cardiac Output Monitor into their standard of care. Morris Nguyen
费森尤斯公司医疗保健企业投资
11投资
费森尤斯医疗企业账本11投资。他们最新的投资网医疗作为他们的一部分B系列在2022年7月7日。
费森尤斯公司医疗企业的投资活动
日期 |
轮 |
公司 |
量 |
新的吗? |
共同投资者 |
来源 |
---|---|---|---|---|---|---|
7/18/2022 |
B系列 |
网医疗 |
15美元 |
是的 |
2 |
|
2/16/2022 |
B - II系列 |
备忘录疗法 |
24.91美元 |
是的 |
3 |
|
11/8/2021 |
B系列 |
SafeRide健康 |
|
没有 |
1 |
|
3/2/2021 |
C系列 |
|||||
10/1/2020 |
B系列 |
日期 |
7/18/2022 |
2/16/2022 |
11/8/2021 |
3/2/2021 |
10/1/2020 |
---|---|---|---|---|---|
轮 |
B系列 |
B - II系列 |
B系列 |
C系列 |
B系列 |
公司 |
网医疗 |
备忘录疗法 |
SafeRide健康 |
||
量 |
15美元 |
24.91美元 |
|
||
新的吗? |
是的 |
是的 |
没有 |
||
共同投资者 |
|||||
来源 |
2 |
3 |
1 |
费森尤斯医疗企业账本投资退出
2投资退出
费森尤斯医疗企业账本有2投资组合出口。他们最新的投资退出SafeRide健康 在2022年7月20日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自国家申请或者新闻,由VentureSource的提供,或基于比较数据的估值模型。
|
收购者 |
来源 |
---|---|---|---|---|---|
7/20/2022 |
收购了 |
2 |
|||
日期 |
7/20/2022 |
|
---|---|---|
退出 |
收购了 |
|
公司 |
||
估值 |
||
收购者 |
||
来源 |
2 |
费森尤斯医疗企业账本团队
2团队成员
费森尤斯医疗企业账本有2 团队成员,包括当前的董事总经理,亚历山德拉Dambeck。
的名字 |
工作经历 |
标题 |
状态 |
---|---|---|---|
亚历山德拉Dambeck |
|
董事总经理 |
当前的 |
的名字 |
亚历山德拉Dambeck |
|
---|---|---|
工作经历 |
|
|
标题 |
董事总经理 |
|
状态 |
当前的 |
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。